Daniel Victor Ortigoza։ Lipoprotein(a) Levels Predict Long-Term Cardiovascular Risk in Women
Daniel Victor Ortigoza, 2nd Vice President of the Cardio-Oncology Committee at the Argentine Federation of Cardiology and President of the Arrhythmias and Electrophysiology Committee of the Argentine Federation of Cardiology, shared a post on LinkedIn about a recent article by Tybjærg Nordestgaard et al, published in JAMA Cardiology:
”Thirty-Year Risk of Cardiovascular Disease Among Healthy Women According to Clinical Thresholds of Lipoprotein(a). Ask Tybjærg Nordestgaard et al.
Lipoprotein(a) (LP(a) levels are known to be genetically determined, and elevated levels are (for now) an independent and unmodifiable risk factor for cardiovascular disease (CVD).
A 30-year prospective follow-up study was conducted in healthy women, primarily of European descent, comparing baseline LP(a) levels, clinical thresholds, LP(a) percentiles, and a specific genotype to establish the probability of developing CVD.
Figure 1. Restricted Cubic Spline Curves of 30-Year Hazard Ratios (HRs) for Major Cardiovascular Events (A), Coronary Heart Disease (B), Ischemic Stroke (C), and Cardiovascular Death (D)
- On the X-axis (baseline levels), analyze LP(a) levels; on the Y-axis, analyze HR (>1 => Risk). On the Y-axis, Graph A: HR for MACE, B: CHD, C: Stroke and D: Death.
- Color zone: Lp(a) levels, green: LP(a) < 10, blue < 30, etc.
- Vertical dotted lines indicating different percentiles.
- The gray band represents the HR width; the narrower the band, the greater the accuracy of the data.
- ight vertical line: Density percentage: referring to the LP (a) with respect to the total population under study.
Interpretation of the graph:
- In CVD the strongest associated risk is obtained with LP ( a) > 150mg/dl ( red) ( HR=2.5)
- In MACE the risk associated with LP ( a) > 100 mg/dl ( HR: 1.8)
- It carries moderate risks in stroke and cardiac death.
- Only women with Lp(a) levels > 30 mg/dl or above the 75th percentile were associated with major cardiovascular disease.”
Title: Thirty-Year Risk of Cardiovascular Disease Among Healthy Women According to Clinical Thresholds of Lipoprotein(a)
Authors: Tybjærg Nordestgaard, Daniel I. Chasman, Vinayaga Moorthy, Jordan M. Kraaijenhof, Nancy R. Cook, I-Min Lee, Julie E. Buring, Paul M. Ridker
Read the Full Article on JAMA Cardiology․

Stay updated on all scientific advances with Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS